Medivir Appoints Christina Herder as Executive VP Strategic Business Development
STOCKHOLM, Sweden , Nov. 10, 2017 /PRNewswire/ -- Medivir AB (NASDAQ: MVIR) (Stockholm: MVIR) announces today the appointment of Christina Herder, as Executive Vice President, Strategic Business Development effective December 14, 2017. Christina will report to CEO Christine Lind and will join Medivir's executive management team.The addition of Christina at Medivir fills an important role focusing in the near-term on out-licensing of Medivir's projects that could benefit from the capabilities of a partner, whether at late stages of clinical development or early stages of research. Christina will also be responsible for leading any in-licensing or acquisition of projects that are synergistic with Medivir's scientific areas of expertise, as well as managing alliances with existing partners.
Christina has 25 years experience of supporting drug development in the areas of corporate and business development, strategy and project management. Her most recent employment was as CEO of Modus Therapeutics. Prior to Modus, Christina held various leadership positions at Sobi AB (and previously Biovitrum), including in Corporate Development, Licensing, and Portfolio and Project Management. She began her career at Pharmacia & Upjohn. Christina earned a PhD in Physical Chemistry from the Royal Institute of Technology from KTH in Stockholm, and holds an MBA from Stockholm University.
"I am very excited to join Medivir, with its broad pipeline supported by scientific excellence. I look forward to building on Medivir's existing strong reputation in the pharmaceutical community by bringing new value creating partnerships to the company," comments Christina Herder.
"It gives me great pleasure to welcome Christina to Medivir. Her strategic experiences in drug development companies and as well as her skills in the specific area of licensing make her an excellent addition to Medivir's executive team," says Christine Lind, CEO at Medivir.
For further information, please contact:
Medivir is a research-based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical needs. Medivir is listed on the Nasdaq Stockholm Mid Cap List.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
http://mb.cision.com/Main/652/2387213/749121.pdf Press release (PDF)
Company Codes: Bloomberg:MVIRB@SS, Frankfurt:MVR, OTC-PINK:MVRBY, ISIN:SE0000273294, LSE:0GP7, OTC-PINK:MVRBF, RICS:MVIRB.ST, Stockholm:MVIRB